Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

2 weeks ago 9

Attiya Zainib

Mon, August 10, 2026 astatine 8:09 AM CDT 4 min read

Brown Advisory, an concern absorption company, released its "Brown Advisory Global Leaders Strategy" for the 2nd 4th of 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. Brown Advisory's Global Leaders Strategy delivered a nett instrumentality of 4.6% successful the 2nd 4th of 2026, underperforming its benchmark, the MSCI ACWI Net Index, which returned 14.9%. The comparative weakness was driven chiefly by underexposure to semiconductors and exertion hardware, portion software, unreality services, and fiscal holdings besides weighed connected performance. The strategy benefited from holdings successful areas tied to AI infrastructure, with semiconductor vulnerability and AI-related investments gaining from beardown demand. Looking ahead, Brown Advisory sees an charismatic situation for progressive stock-picking, with its ready-to-buy database astatine its highest level since the COVID-19 play and an estimated 12%-13% mean five-year base-case IRR, portion maintaining a absorption connected quality, valuation discipline, and semipermanent cash-flow generation. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Brown Advisory Global Leaders Strategy Fund highlighted stocks similar Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS) is simply a planetary carnal wellness institution processing medicines, vaccines, and diagnostic products for livestock and companion animals. The one-month instrumentality of Zoetis Inc. (NYSE:ZTS) was -3.62% portion its shares traded betwixt $71.47 and $160.48 implicit the past 52 weeks. On August 7, 2026, Zoetis Inc. (NYSE:ZTS) banal closed astatine astir $77.27 per share, with a marketplace capitalization of astir $30.02 billion.

Brown Advisory Global Leaders Strategy Fund stated the pursuing regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 capitalist letter:

We exited Zoetis Inc. (NYSE:ZTS) in May. We were attracted to the concern owed to its presumption arsenic the largest pure-play carnal wellness company, benefiting from important standard successful R&D and as the highest-quality marketer to veterinarians and livestock producers, which increases switching costs. The institution had further shifted its concern premix meaningfully toward a higher and much profitable publication from its companion carnal segment. Our investment successful Zoetis began to look accrued maturation headwinds successful 2025 owed to incremental contention successful its industry-leading dermatology and Simparica Trio products. Additionally, the motorboat of Librela—the archetypal disposable therapy for osteoarthritis symptom in dogs—underperformed our expectations. Furthermore, we person observed increased competition crossed Zoetis's main franchises and, astir recently, Zoetis besides saw generic competition successful therapeutic categories. Several concerns person emerged: (1) contempt the high barriers to introduction successful carnal health, contention successful the assemblage has intensified during our ownership; (2) we bash not person capable visibility connected their pipeline to measure the way of future publication astatine this point; and (3) we misinterpreted Zoetis's quality to lend to the portfolio from a deferrable request perspective, arsenic it did not present the defensiveness we expected. As such, we spot our concern thesis successful Zoetis arsenic breached and person fully exited the position.

Read Entire Article